Literature DB >> 18499387

The prognostic value of neuron-specific enolase in head trauma patients.

Emine Meric1, Abdulkadir Gunduz, Suleyman Turedi, Ertugrul Cakir, Mustafa Yandi.   

Abstract

In recent years, in addition to neurological examination and neuroradiologic examinations, attempts have been made to assess the severity of post-traumatic brain injury and to obtain an early idea of patient prognosis using biochemical markers with a high degree of brain tissue specificity. One such enzyme is neuron-specific enolase (NSE). This study investigates the correlation between serum NSE levels, Glasgow Coma Score, and prognosis measured by Glasgow Outcome Scores in head trauma patients. This was a prospective study conducted with 80 trauma patients presenting to the Emergency Department. Patients were divided into four groups. The first group consisted of patients with general body trauma, but no head trauma. The second group had minor head trauma. The third group had moderate head trauma, and the fourth group had severe head trauma. The relationship between subjects' admission NSE levels and admission and discharge Glasgow Coma Scores (GCS) and Glasgow Outcome Scores (GOS) 1 month later was examined. A receiver operating characteristic (ROC) analysis was performed using a serum NSE cutoff level of 20.52 ng/mL and a GOS of 3 or less as the definition of poor neurologic outcome. There was a significant difference in the NSE levels between group 1 (general trauma) and group 3 (moderate head trauma). There was also a statistically significant difference in NSE levels between group 1 (general trauma) and group 4 (severe head trauma) (p < 0.05). There was a statistically significant inverse relationship between NSE levels and GOS as determined within groups 3 (moderate) and 4 (severe head trauma) (p < 0.05). When NSE levels were compared with admission GCS, it was found that GCS fell as NSE levels rose. There was no significant correlation between NSE and GCS within groups 3 (moderate) or 4 (severe). There was a statistically significant correlation within group 2 (mild) (p < 0.05). By ROC analysis, serum NSE was 87% sensitive and 82.1% specific in predicting poor neurologic outcome in the study patients. The area under the curve was 0.931. This study shows that initial serum NSE levels in moderate and severe head trauma patients correlate inversely with GOS 1 month later, but only within the moderate and severe head trauma groups. However, serum NSE was 87% sensitive and 82.1% specific in predicting poor neurologic outcome in all of the study patients. This derived cutoff value now needs to be prospectively validated. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18499387     DOI: 10.1016/j.jemermed.2007.11.032

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  27 in total

1.  Role of Brain Biomarker in Predicting Clinical Outcome in Hypertensive Cerebrovascular Ischemic Stroke.

Authors:  Anuradha Bharosay; Vivek Vikram Bharosay; Kiran Saxena; Meena Varma
Journal:  Indian J Clin Biochem       Date:  2017-05-20

Review 2.  Current status of fluid biomarkers in mild traumatic brain injury.

Authors:  Jacqueline R Kulbe; James W Geddes
Journal:  Exp Neurol       Date:  2015-05-14       Impact factor: 5.330

Review 3.  Biomarkers in traumatic brain injury.

Authors:  Richa Sharma; Daniel T Laskowitz
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

4.  Acute serum hormone levels: characterization and prognosis after severe traumatic brain injury.

Authors:  Amy K Wagner; Emily H McCullough; Christian Niyonkuru; Haishin Ozawa; Tammy L Loucks; Julie A Dobos; Christopher A Brett; Martina Santarsieri; C Edward Dixon; Sarah L Berga; Anthony Fabio
Journal:  J Neurotrauma       Date:  2011-06-01       Impact factor: 5.269

5.  Predictive value of neuron-specific enolase for prognosis in patients with moderate or severe traumatic brain injury: a systematic review and meta-analysis.

Authors:  Eric Mercier; Amélie Boutin; Michèle Shemilt; François Lauzier; Ryan Zarychanski; Dean A Fergusson; Lynne Moore; Lauralyn A McIntyre; Patrick Archambault; France Légaré; François Rousseau; François Lamontagne; Linda Nadeau; Alexis F Turgeon
Journal:  CMAJ Open       Date:  2016-07-22

6.  Hypobaric hypoxia exacerbates the neuroinflammatory response to traumatic brain injury.

Authors:  Michael D Goodman; Amy T Makley; Nathan L Huber; Callisia N Clarke; Lou Ann W Friend; Rebecca M Schuster; Stephanie R Bailey; Stephen L Barnes; Warren C Dorlac; Jay A Johannigman; Alex B Lentsch; Timothy A Pritts
Journal:  J Surg Res       Date:  2010-06-16       Impact factor: 2.192

7.  UCH-L1 is a Poor Serum Biomarker of Murine Traumatic Brain Injury After Polytrauma.

Authors:  Mackenzie C Morris; Aron Bercz; Grace M Niziolek; Farzaan Kassam; Rose Veile; Lou Ann Friend; Timothy A Pritts; Amy T Makley; Michael D Goodman
Journal:  J Surg Res       Date:  2019-07-03       Impact factor: 2.192

8.  Effect of Danshen aqueous extract on serum hs-CRP, IL-8, IL-10, TNF-α levels, and IL-10 mRNA, TNF-α mRNA expression levels, cerebral TGF-β1 positive expression level and its neuroprotective mechanisms in CIR rats.

Authors:  Xue-Yun Liang; Hai-Ning Li; Xiao-Yan Yang; Wen-Yan Zhou; Jian-Guo Niu; Ben-Dong Chen
Journal:  Mol Biol Rep       Date:  2013-02-02       Impact factor: 2.316

Review 9.  Blood biomarkers for brain injury: What are we measuring?

Authors:  Keisuke Kawata; Charles Y Liu; Steven F Merkel; Servio H Ramirez; Ryan T Tierney; Dianne Langford
Journal:  Neurosci Biobehav Rev       Date:  2016-05-12       Impact factor: 8.989

10.  Admission plasma levels of the neuronal injury marker neuron-specific enolase are associated with mortality and delirium in sepsis.

Authors:  Jason D Christie; Nuala J Meyer; Brian J Anderson; John P Reilly; Michael G S Shashaty; Jessica A Palakshappa; Alex Wysoczanski; Thomas G Dunn; Altaf Kazi; Anna Tommasini; Mark E Mikkelsen; William D Schweickert; Dennis L Kolson
Journal:  J Crit Care       Date:  2016-06-23       Impact factor: 3.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.